TrialNeuro-oncology2015
Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study.
L Burt Nabors et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
144 papers cite itlatest 60 shown
this paperpooled ittrialcites it